Open an account

BeOne Medicines AG

ONC · SHANGHAI

$377.63−$4.64 (−1.21%)TodayMarket closed ·
Prev close $382.27

About ONC

BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,825 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Employees
11,825
Headquarters
Basel, Basel-Stadt
Listed
Mar 2, 2016
Sector
Health Care
Industry
Biotechnology
Website
beonemedicines.com

ONC key statistics

Market cap
282.08B
Price-earnings ratio
0.00
Dividend yield
0.12%
Average volume
385.96K
Volume
315.81K
Open price
$379.05
High today
$384.40
Low today
$372.65
52 Week high
$388.66
52 Week low
$253.95

BeOne Medicines AG (ONC) at a glance

As of Oct 23, 2026, BeOne Medicines AG (ONC) shares are priced at $377.63, giving the company a market cap of 282.08B, a price-to-earnings ratio of 0.00 and a dividend yield of 0.12%.

Today the stock has traded between $372.65 and $384.40. The current price is 1.3% above the day's low and 1.8% below its high.

Volume so far is 315.81K shares, in line with the average of 385.96K shares a day.

Over the past year BeOne Medicines AG has ranged from $253.95 to $388.66, and now sits 92% of the way up that range.

BeOne Medicines AG met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $13.84 per share against an estimate of $0.00.

The average analyst price target is $547.66, 45.0% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 14 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $547.66
Low
$441.87
Now
$377.63
High
$682.59

ONC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 774.4% on average.

  1. Q2 FY24: reported -$8.33 per share against an estimate of -$0.9191
  2. Q3 FY24: reported -$0.645 per share against an estimate of -$0.5252
  3. Q4 FY24: reported $22.65 per share against an estimate of $1.19
  4. Q2 FY25: reported $0.39 per share against an estimate of $0.0303
  5. Q3 FY25: reported $0.573 per share against an estimate of $0.606
  6. Q4 FY25: reported $0.283 per share against an estimate of $0.6262
  7. Q1 FY26: reported $1.04 per share against an estimate of $0.4949
  8. Q2 FY26: reported $13.84 per share against an estimate of $0.00

ONC news

  • Press releaseBusiness Wire

    BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

  • Press releaseBusiness Wire

    BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

  • Press releaseBusiness Wire

    BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

  • Press releaseBusiness Wire

    BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

  • Namrata Sen

    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

  • Press releaseBusiness Wire

    BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

  • Press releaseBusiness Wire

    BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

  • Vandana Singh

    Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

Similar companies

Companies in the same industry as BeOne Medicines AG

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.